在轻度认知障碍中精神病症状的发生率:系统性审查和元分析
Aline Berger1, Raphael Machado Castilhos2, Zahinoor Ismail3
1Programa de Pós-Graduação em Ciências Médicas da Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
Ageing research reviews
|July 19, 2024
概括
像幻觉和妄想这样的精神病症状在轻度认知障碍 (MCI) 中不常见. 它们的流行程度受评估方法和样本特征的影响,突出显示了MCI研究中需要标准化的方法.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 老年学是一门学科.
背景情况:
- 神经精神症状可能会影响轻度认知障碍 (MCI) 的预后.
- 关于MCI患者精神病症状的频率的数据有限.
- 了解这些症状对于准确的诊断和管理至关重要.
研究的目的:
- 系统地审查和估计患有MCI的个体中幻觉和妄想的患病率.
- 探索导致报告流行率异质性的因素.
主要方法:
- 在MEDLINE,EMBASE和PsychoINFO数据库中进行全面的文献搜索,截至2023年6月.
- 包括36项研究,包括20426名患有MCI的患者.
- 应用随机效应模型来估计患病率,使用子组和元回归分析来解决异质性问题.
主要成果:
- 幻觉的总流行率为1.78% (95% CI,1.17-2.71),幻觉的总流行率为3.84% (95% CI,2.71-5.42).
- 观察到显著的异质性 (I2 = 90%).
- 在使用神经精神病学库存 (NPI) 尺度和基于人口的样本的研究中,患病率较低.
结论:
- 在轻度认知障碍患者中,幻觉和妄想的发生率较低.
- 评估方法和样本来源是影响报告流行率的重要因素.
- 研究的异质性可以部分由这些方法变化来解释.
相关概念视频
Negative and Cognitive Symptoms of Schizophrenia
48
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
48
Diagnostic and Statistical Manual of Mental Disorders (DSM)
54
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
54
Psychological and Sociocultural Causes of Schizophrenia
82
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
82
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Cognitive Development During Adulthood
78
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
78
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114


